322 related articles for article (PubMed ID: 20154418)
41. N- and C-terminal modifications of nociceptin/orphanin FQ generate highly potent NOP receptor ligands.
Guerrini R; Caló G; Lambert DG; Carrá G; Arduin M; Barnes TA; McDonald J; Rizzi D; Trapella C; Marzola E; Rowbotham DJ; Regoli D; Salvadori S
J Med Chem; 2005 Mar; 48(5):1421-7. PubMed ID: 15743186
[TBL] [Abstract][Full Text] [Related]
42. Ro 64-6198 [(1S,3aS)-8-(2,3,3a,4,5,6-Hexahydro-1H-phenalen-1-yl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-one] acts differently from nociceptin/orphanin FQ in rat periaqueductal gray slices.
Chiou LC; Chuang KC; Wichmann J; Adam G
J Pharmacol Exp Ther; 2004 Nov; 311(2):645-51. PubMed ID: 15254141
[TBL] [Abstract][Full Text] [Related]
43. Pharmacological characterization of the novel nociceptin/orphanin FQ receptor ligand, ZP120: in vitro and in vivo studies in mice.
Rizzi A; Rizzi D; Marzola G; Regoli D; Larsen BD; Petersen JS; Calo' G
Br J Pharmacol; 2002 Oct; 137(3):369-74. PubMed ID: 12237257
[TBL] [Abstract][Full Text] [Related]
44. Participation of the nociceptin/orphanin FQ receptor in ethanol-mediated locomotor activation and ethanol intake in preweanling rats.
Miranda-Morales RS; Nizhnikov ME; Waters DH; Spear NE
Behav Brain Res; 2013 May; 245():137-44. PubMed ID: 23439216
[TBL] [Abstract][Full Text] [Related]
45. Effects of receptor density on Nociceptin/OrphaninFQ peptide receptor desensitisation: studies using the ecdysone inducible expression system.
Barnes TA; McDonald J; Rowbotham DJ; Duarte TL; Lambert DG
Naunyn Schmiedebergs Arch Pharmacol; 2007 Nov; 376(3):217-25. PubMed ID: 17899014
[TBL] [Abstract][Full Text] [Related]
46. Identification of an achiral analogue of J-113397 as potent nociceptin/orphanin FQ receptor antagonist.
Trapella C; Guerrini R; Piccagli L; Calo' G; Carra' G; Spagnolo B; Rubini S; Fanton G; Hebbes C; McDonald J; Lambert DG; Regoli D; Salvadori S
Bioorg Med Chem; 2006 Feb; 14(3):692-704. PubMed ID: 16202610
[TBL] [Abstract][Full Text] [Related]
47. Nociceptin/orphanin FQ receptor antagonists as innovative antidepressant drugs.
Gavioli EC; Calo' G
Pharmacol Ther; 2013 Oct; 140(1):10-25. PubMed ID: 23711793
[TBL] [Abstract][Full Text] [Related]
48. Further evidence for an involvement of nociceptin/orphanin FQ in the pathophysiology of Parkinson's disease: a behavioral and neurochemical study in reserpinized mice.
Volta M; Mabrouk OS; Bido S; Marti M; Morari M
J Neurochem; 2010 Dec; 115(6):1543-55. PubMed ID: 20950413
[TBL] [Abstract][Full Text] [Related]
49. Antagonistic effects of CompB on orphanin FQ-induced colonic contractions in rats.
Tada H; Nakagawa K; Yamamura T; Takahashi T
Eur J Pharmacol; 2002 Nov; 454(1):53-8. PubMed ID: 12409005
[TBL] [Abstract][Full Text] [Related]
50. Roles of μ-opioid receptors and nociceptin/orphanin FQ peptide receptors in buprenorphine-induced physiological responses in primates.
Cremeans CM; Gruley E; Kyle DJ; Ko MC
J Pharmacol Exp Ther; 2012 Oct; 343(1):72-81. PubMed ID: 22743574
[TBL] [Abstract][Full Text] [Related]
51. Brain and whole-body imaging in rhesus monkeys of 11C-NOP-1A, a promising PET radioligand for nociceptin/orphanin FQ peptide receptors.
Kimura Y; Fujita M; Hong J; Lohith TG; Gladding RL; Zoghbi SS; Tauscher JA; Goebl N; Rash KS; Chen Z; Pedregal C; Barth VN; Pike VW; Innis RB
J Nucl Med; 2011 Oct; 52(10):1638-45. PubMed ID: 21880575
[TBL] [Abstract][Full Text] [Related]
52. In vitro binding and functional studies of Ac-RYYRIK-ol and its derivatives, novel partial agonists of the nociceptin/orphanin F/Q receptor.
Gunduz O; Sipos F; Spagnolo B; Kocsis L; Magyar A; Orosz G; Borsodi A; Calò G; Benyhe S
Neurosignals; 2006-2007; 15(2):91-101. PubMed ID: 16874009
[TBL] [Abstract][Full Text] [Related]
53. Novel non-peptide nociceptin/orphanin FQ receptor agonist, 1-[1-(1-Methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl]-1H-benzimidazole: design, synthesis, and structure-activity relationship of oral receptor occupancy in the brain for orally potent antianxiety drug.
Hayashi S; Hirao A; Imai A; Nakamura H; Murata Y; Ohashi K; Nakata E
J Med Chem; 2009 Feb; 52(3):610-25. PubMed ID: 19125610
[TBL] [Abstract][Full Text] [Related]
54. Chronic high-NaCl intake prolongs the cardiorenal responses to central N/OFQ and produces regional changes in the endogenous brain NOP receptor system.
Wainford RD; Kapusta DR
Am J Physiol Regul Integr Comp Physiol; 2009 Feb; 296(2):R280-8. PubMed ID: 18987291
[TBL] [Abstract][Full Text] [Related]
55. Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist.
Linz K; Christoph T; Tzschentke TM; Koch T; Schiene K; Gautrois M; Schröder W; Kögel BY; Beier H; Englberger W; Schunk S; De Vry J; Jahnel U; Frosch S
J Pharmacol Exp Ther; 2014 Jun; 349(3):535-48. PubMed ID: 24713140
[TBL] [Abstract][Full Text] [Related]
56. Modulation of silent and constitutively active nociceptin/orphanin FQ receptors by potent receptor antagonists and Na+ ions in rat sympathetic neurons.
Mahmoud S; Margas W; Trapella C; Caló G; Ruiz-Velasco V
Mol Pharmacol; 2010 May; 77(5):804-17. PubMed ID: 20159949
[TBL] [Abstract][Full Text] [Related]
57. Development of LC-MS/MS-based receptor occupancy tracers and positron emission tomography radioligands for the nociceptin/orphanin FQ (NOP) receptor.
Pedregal C; Joshi EM; Toledo MA; Lafuente C; Diaz N; Martinez-Grau MA; Jiménez A; Benito A; Navarro A; Chen Z; Mudra DR; Kahl SD; Rash KS; Statnick MA; Barth VN
J Med Chem; 2012 Jun; 55(11):4955-67. PubMed ID: 22541041
[TBL] [Abstract][Full Text] [Related]
58. UFP-101, a peptide antagonist selective for the nociceptin/orphanin FQ receptor.
Calo G; Guerrini R; Rizzi A; Salvadori S; Burmeister M; Kapusta DR; Lambert DG; Regoli D
CNS Drug Rev; 2005; 11(2):97-112. PubMed ID: 16007234
[TBL] [Abstract][Full Text] [Related]
59. Pharmacological studies on the NOP and opioid receptor agonist PWT2-[Dmt
Cerlesi MC; Ding H; Bird MF; Kiguchi N; Ferrari F; Malfacini D; Rizzi A; Ruzza C; Lambert DG; Ko MC; Calo G; Guerrini R
Eur J Pharmacol; 2017 Jan; 794():115-126. PubMed ID: 27871910
[TBL] [Abstract][Full Text] [Related]
60. Mu-opioid peptide (MOP) and nociceptin/orphanin FQ peptide (NOP) receptor activation both contribute to the discriminative stimulus properties of cebranopadol in the rat.
Tzschentke TM; Rutten K
Neuropharmacology; 2018 Feb; 129():100-108. PubMed ID: 29155273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
